Patents by Inventor David Robert Micklem

David Robert Micklem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Axl Antagonistic Antibodies
    Publication number: 20240190972
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: June 29, 2023
    Publication date: June 13, 2024
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • Anti-AXL Antagonistic Antibodies
    Publication number: 20230406941
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: February 17, 2023
    Publication date: December 21, 2023
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Anti-axl antagonistic antibodies
    Patent number: 11732048
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: August 22, 2023
    Assignees: Bergen Teknologioverføring AS, BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
  • Anti-Axl antagonistic antibodies
    Patent number: 11584796
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 21, 2023
    Assignees: BERGENBIO ASA, BERGEN TEKNOLOGIOVERFØRING AS
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Hodneland Nilsson, Tone Sandal
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20220195054
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: November 2, 2021
    Publication date: June 23, 2022
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • ANTI-AXL ANTIBODIES
    Publication number: 20220185897
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: October 18, 2021
    Publication date: June 16, 2022
    Applicant: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Anti-Axl antagonistic antibodies
    Patent number: 11198734
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 14, 2021
    Assignees: Bergen Teknologioverføring AS, BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
  • Anti-Axl antibodies
    Patent number: 11186643
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 30, 2021
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Biomarkers for cancer
    Patent number: 11035008
    Abstract: The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 15, 2021
    Assignee: BerGenBio ASA
    Inventors: Monica Hellesoy, Linn Hodneland Nilsson, David Robert Micklem
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20210171643
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: June 21, 2017
    Publication date: June 10, 2021
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • ANTI-AXL ANTAGONISTIC ANTIBODIES
    Publication number: 20190177419
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 13, 2019
    Applicants: BERGEN TEKNOLOGIOVERFORING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Anti-Axl antagonistic antibodies
    Patent number: 10208121
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 19, 2019
    Assignees: BERGEN TEKNOLOGIOVERFORING AS, BERGEBIO ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Hodneland Nilsson, Tone Sandal
  • ANTI-AXL ANTIBODIES
    Publication number: 20180371096
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 27, 2018
    Applicant: BerGenBio ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, Linn Hodneland NILSSON, Lavina AHMED, Hallvard HAUGEN
  • METHODS USING AXL AS A BIOMARKER OF EPITHELIAL-TO-MESENCHYMAL TRANSITION
    Publication number: 20180246080
    Abstract: The present invention relates to the use of Axl as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject. More specifically, the invention relates to various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Axl expression and/or activity.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 30, 2018
    Applicant: BERGEN TEKNOLOGIOVERFORING AS
    Inventors: James Bradley Lorens, David Robert Micklem, Lars A. Akslen
  • BIOMARKERS FOR CANCER
    Publication number: 20180208989
    Abstract: The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 26, 2018
    Applicant: BERGENBIO ASA
    Inventors: Monica HELLESOY, Linn Hodneland NILSSON, David Robert MICKLEM
  • Anti-Axl antibodies
    Patent number: 9975954
    Abstract: Antibodies characterized by their variable sequences/CDRs which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 22, 2018
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Anti-Axl antibodies
    Patent number: 9975953
    Abstract: Antibodies which specifically bind to the Ax I protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 22, 2018
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • ANTI-AXL ANTAGONISTIC ANTIBODIES
    Publication number: 20170349658
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 7, 2017
    Applicants: BERGEN TEKNOLOGIOVERFORING AS, BERGENBIO AS
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • SLFN11 AS BIOMARKER FOR AML
    Publication number: 20170314077
    Abstract: The use of Slfn11 as a biomarker for detecting the occurrence of epithlial-to-mesenchymal transition (EMT) in a subject, and the use of Slfn11 modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Slfn11 expression and/or activity.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 2, 2017
    Applicant: BERGENBIO AS
    Inventors: David Robert MICKLEM, Monica HELLESOY, Linn Hodneland NILSSON
  • Use of kinase inhibitors
    Patent number: 9801880
    Abstract: The invention provides a compound for use for treating, preventing or managing a condition associated with the activation, mutation and/or over-expression of one or more kinases, wherein if the condition is associated with Axl over-expression, it is also associated with the activation, mutation and/or over-expression of one or more other kinases, and wherein the compound has a structure according to formula (I) : wherein the symbols used in formula (I) are as defined herein.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: October 31, 2017
    Assignee: BerGenBio AS
    Inventor: David Robert Micklem